Schedule II Opioids and Stimulants & CMV Crash Risk and Driver Performance: Evidence Report and Systematic Review

Details

• Creators:
  Brittle, Christine ; Fiedler, Katherine ; Cotterman, Chris
• Corporate Creators:
  Acclaro Research Solutions, Inc.
• Subject/TRT Terms:
  Commercial Vehicles Driver Performance Drug Use Fatalities Literature Reviews Motor Carriers Risk Assessment Stimulants Truck Crashes
• Publication/ Report Number:
  DTMC75-13-R-00007
• DOI:
  https://doi.org/10.21949/1503007
• Resource Type:
  Tech Report
• Geographical Coverage:
  United States
• Corporate Publisher:
  United States. Federal Motor Carrier Safety Administration
• Abstract:
  Driving a large commercial truck is dangerous work. Truck drivers have a fatal work injury
  
  rate of 22.1 per 100,000 workers, the eighth highest in the nation.1
  
  According to the Federal
  
  Motor Carrier Safety Administration (FMCSA), large trucks were involved in 3,568 fatal
  
  crashes in 2011, killing 4,108 people and costing the U.S. $39 billion.2
  
  The primary mission of the FMCSA is to reduce these crashes, injuries, and fatalities. As a
  
  part of this mission, its Medical Programs Division works to ensure that commercial motor
  
  vehicle (CMV) drivers engaged in interstate commerce are physically qualified and able to
  
  safely perform their work. In order to improve safety the FMCSA commissions systematic
  
  reviews on a variety of topics. These findings, together with input from FMCSA’s Medical
  
  Expert Panel, are used to inform policy and decision-making.
  
  This systematic review focuses on the effects that licit use of prescribed Schedule II drugs
  
  have on the risk of CMV crashes or on indirect measures of driver performance.
  
  Schedule II drugs includes a variety of stimulants (such as amphetamine, methamphetamine,
  
  and methylphenidate), depressants (such as pentobarbital, glutethimide, and phencyclidine),
  
  and a large number of opioids (including codeine, morphine, hydrocodone, oxycodone, and
  
  methadone). While these substances have acceptable medical uses, they also carry high
  
  potential for impairment and abuse. This report focuses specifically on the effects of licit use
  
  of Schedule II stimulants and opioids.
  
  
• Format:
  PDF
• Collection(s):
  Federal Motor Carrier Safety Administration
• Main Document Checksum:
  urn:sha256:fb43a1f94632bca16121bf13b6ba01365d9faf66031e6ef0d3e3672a52d0a6a4
• Download URL:
  https://rosap.ntl.bts.gov/view/dot/200/dot_200_DS1.pdf
• File Type:
  [PDF - 1.83 MB ]